Page last updated: 2024-11-01

omeprazole and Cutaneous T-Cell Lymphoma

omeprazole has been researched along with Cutaneous T-Cell Lymphoma in 1 studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tröger, U1
Stötzel, B1
Martens-Lobenhoffer, J1
Gollnick, H1
Meyer, FP1

Other Studies

1 other study available for omeprazole and Cutaneous T-Cell Lymphoma

ArticleYear
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.
    BMJ (Clinical research ed.), 2002, Jun-22, Volume: 324, Issue:7352

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Benzimidazoles; Dermatologic Agents; Dru

2002